Our results suggest that CFL1 may be a promising prognostic biomarker and new therapeutic target for HCC, and the natural xanthone NJXA might be a potential inhibitor of CFL1 in HCC. This evidence concerns the gene CFL1 and hepatocellular carcinoma.